COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Corticosteroids and Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01798420
Recruitment Status : Completed
First Posted : February 25, 2013
Last Update Posted : February 25, 2013
Information provided by (Responsible Party):
George Habib, The Nazareth Hospital, Israel

Brief Summary:
Corticosteroid treatment in diabetic patients admitted for COPD exacerbation are expected to significantly increase hemoglobin A1C levels

Condition or disease
Diabetes Chronic Obstructive Pulmonary Disease

Detailed Description:
HbA1C levels were evaluated in diabetic patients with COPD exacerbation on admission to the hospital and 3-months later. Demographic, clinical, laboratory variables and total steroid dose were documented. Age- and sex-matched group of diabetic patients with COPD who were admitted for other reasons, were asked to participate as a control group. Mann-Whitney and Chi square/Fischer's exact tests were used to compare between the parameters of the two groups. Wilcoxon signed rank test was used to compare between HbA1C levels at baseline and 3 months later. Multi-variate linear regression analysis was used to find predictors for increase in HbA1C levels in the patients' group.

Layout table for study information
Study Type : Observational
Actual Enrollment : 42 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: The Impact of Corticosteroid Treatment on Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation
Study Start Date : April 2012
Actual Primary Completion Date : September 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: A1C Steroids

non-corticosteroid group

Primary Outcome Measures :
  1. Hemoglobin A1C LEVEL [ Time Frame: 3 MONTHS ]

Secondary Outcome Measures :
  1. Glucose levels [ Time Frame: 3 months ]

Other Outcome Measures:
  1. Weight [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diabetic patients with COPD ecaxerbation who are admitted to the hospital

Inclusion Criteria:

  • Diabetic patients with COPD exacerbation

Exclusion Criteria:

  • Patients treated with steroids during the previous 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01798420

Layout table for location information
Department of medicine
Nzareth, Nazareth, Israel, 16000
Sponsors and Collaborators
The Nazareth Hospital, Israel
Layout table for additonal information
Responsible Party: George Habib, Head, Rheumatology clinic, Nzareth hospital, Nzareth, The Nazareth Hospital, Israel Identifier: NCT01798420    
Other Study ID Numbers: Hb-A1C-2012
First Posted: February 25, 2013    Key Record Dates
Last Update Posted: February 25, 2013
Last Verified: February 2013
Keywords provided by George Habib, The Nazareth Hospital, Israel:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases